Viridian Therapeutics, Inc. (VRDN) Reports In-Line Q2 EPS

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q2 EPS of ($1.00), in-line with the analyst estimate of ($1.00). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $50.92 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• Amer Sports Inc. (AS) PT Lowered to $42 at Truist, but 'Momentum continues to surge in a tough macro'
• ZeroStack to receive $1B in Memecore tokens in equity deal
• Target raises full-year sales forecast amid ongoing turnaround drive